百濟神州(6160.HK)跳高25.9% 獲全球醫藥巨頭安進27億美元投資
格隆匯11月1日丨百濟神州(6160.HK)跳空高開25.9%,開報105港元,盤前成交65.1萬港元,最新總市值824億港元。中概股百濟神州週四發佈公告稱,與全球醫藥巨頭安進公司建立全球腫瘤戰略合作關係。安進將斥資27億美元,同意為每份百濟神州ADS支付174.85美元,較週四收盤價溢價26%,收購百濟神州20.5%的股份,以此估算對後者的估值約為135億美元。按照每百濟神州1ADS等於13股普通股,折算成港股這邊安進的收購價格為每股105.4港元。據悉,本次合作是中國和美國生物科技領域兩家龍頭企業的強強聯手,是該領域迄今為止金額最大的一次股權投資,也是中國製藥公司國際合作史上的最大交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.